Novartis AG (NVS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

104.280
+0.430+0.41%

Close Nov 22 16:00 ET

104.190
-0.090-0.09%

Pre 08:53 ET

208.48BMarket Cap12.24P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating
Moomoo News22minutes ago · Ratings
Global Equities Roundup: Market Talk
WSJ02:31 ET
Novartis's Midterm Guidance Lift Still Needs to Convince the Market -- Market Talk
WSJ02:31 ET
Barclays Remains a Sell on Novartis AG (NOVN)
TipRanks01:45 ET · Ratings
Novartis AG (NOVN) Gets a Buy From Kepler Capital
TipRanksNov 23 20:46 ET · Ratings
Are Hedge Funds Banking on Novartis AG (NVS)'s Core Income Growth?
Yahoo FinanceNov 23 10:24 ET

Comments

Movers and Shakers

Nov 21 07:11

Columns Today's Pre-Market Movers and Top Ratings | MSTR, NVDA, SNOW, PANW and More

Morning Movers
Gapping up
$Deere (DE.US)$ 's stock rose by 1.6% following their announcement of fourth-quarter earnings that surpassed analyst forecasts, despite substantial market hurdles.
Cryptocurrency-related stocks experienced a widespread surge. $MicroStrategy (MSTR.US)$ saw a significant increase, jumping over 13%, while $MARA Holdings (MARA.US)$ climbed more than 11%.
$Snowflake (SNOW.US)$ 's shares surged 23.3% as ...

Bitcoin climbs closer to $100,000: How high will it go?

10xStockPicks

Nov 15 08:23

ESPR Will Propel Higher, Events This Weekend & Analyst Event Next Week, Stock Price

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...

+18

thz stock ful of sht

Nov 15 01:20

DOWN

$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Johnson & Johnson (JNJ.US)$ $AbbVie (ABBV.US)$ $Merck & Co (MRK.US)$ $ROCHE HOLDING AG (RHHBY.US)$ $Novartis AG (NVS.US)$ $AstraZeneca (AZN.US)$ $Amgen (AMGN.US)$ $Pfizer (PFE.US)$

10xStockPicks

Nov 8 08:28

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary...